Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2026)

Axsome Therapeutics has reported Change in Receivables for 5 years, with the latest figure at $26.6 million in Q1 2026.

• Quarterly Change in Receivables rose 37.13% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.7 million (up 49.54% YoY) and the FY2025 annual result came in at $82.5 million, up 74.78% from the prior year.
• Change in Receivables fell to $26.6 million in Q1 2026 per AXSM's latest filing, from $28.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $37.4 million in Q2 2025 and troughed at -$2.3 million in Q3 2025.
• A 5-year average of $15.7 million and a median of $17.4 million in 2022 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 193.21% in 2025, down 161.75% in 2025.
• Over 5 years, Change in Receivables stood at $17.4 million in 2022, then fell by 5.7% to $16.4 million in 2023, then climbed by 9.14% to $17.9 million in 2024, then soared by 56.14% to $28.0 million in 2025, then fell by 4.86% to $26.6 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $26.6 million, $28.0 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.